The stock of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) is a huge mover today! About 231,038 shares traded hands. CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has risen 372.18% since April 8, 2016 and is uptrending. It has outperformed by 366.53% the S&P500.
The move comes after 6 months positive chart setup for the $765.50M company. It was reported on Nov, 10 by Barchart.com. We have $59.76 PT which if reached, will make NASDAQ:CLCD worth $459.30 million more.
CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Ratings Coverage
Out of 2 analysts covering CoLucid Pharmaceuticals (NASDAQ:CLCD), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. CoLucid Pharmaceuticals has been the topic of 4 analyst reports since August 14, 2015 according to StockzIntelligence Inc. On Thursday, September 3 the stock rating was upgraded by Zacks to “Hold”. William Blair maintained the shares of CLCD in a report on Friday, August 14 with “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, October 24 report. The stock of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has “Buy” rating given on Monday, September 19 by Stifel Nicolaus.
According to Zacks Investment Research, “CoLucid Pharmaceuticals, Inc. is a biopharmaceutical company which develops molecule for the treatment of migraine headaches. The company’s product candidate consists of oral Lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain, which are in different clinical trial. CoLucid Pharmaceuticals, Inc. is headquartered in Burlington, Massachusetts.”
More recent CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on April 26, 2015. Also Fool.com published the news titled: “Why CoLucid Pharmaceuticals Inc. Soared As Much As 18% on Thursday” on September 15, 2016. Prnewswire.com‘s news article titled: “CoLucid Pharmaceuticals, Inc., Raises $37.1 Million in Series C Preferred …” with publication date: January 13, 2015 was also an interesting one.
CLCD Company Profile
CoLucid Pharmaceuticals, Inc., incorporated on August 31, 2005, is a Phase III clinical-stage biopharmaceutical company. The Firm is engaged in developing a small molecule for the acute treatment of migraine headaches. The Company’s product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.